The Study Of Anlotinib Inhibits Biological Behavior Of Human Oral Squamous Cell Carcinoma Cells

Objective Anlotinib is a novel TKIs drug independently developed by our country.It has been proved to have a significant inhibitory effect on a variety of tumors,such as non-small cell lung cancer,kidney cancer,soft tissue sarcoma and so on.It has become the recommended drug in the CSCO Guidelines.However,there are few reports on the application of anlotinib in the treatment of oral squamous cell carcinoma.The effect and mechanism of action are still unclear.This study aims to study the efficacy and potential mechanism of arotinib in the treatment of oral squamous cell carcinoma.By analyzing the effect of arotinib on the biological behavior of human oral squamous cell carcinoma cells and the changes of tumor metastasis related EMT marker gene and protein expression,to clarify the therapeutic effect of arotinib on human oral squamous cell carcinoma and its potential mechanism.Furthermore,a novel targeted therapy scheme was proposed to provide new hope for the treatment of oral squamous cell carcinoma.Methods 1.The effect of anlotinib on the biological behavior of human oral squamous cell carcinoma cells: The effects of anlotinib on human oral squamous cell carcinoma cell lines at gradient concentrations of 0,5,10,15,and 20 μM were detected by cell proliferation assay(CCK-8 method).The cytotoxicity of Cal27 cells was analyzed and the survival curve was drawn.The appropriate drug concentration and action time were screened for follow-up research.The effect of arotinib on the migration ability of human oral squamous cell carcinoma cell line Cal27 cells was preliminarily detected by cell migration experiment(scratch method and Transwell method).2.Changes in the expression levels of EMT marker genes and proteins: RT-q PCR technology and WB technology were used to detect the effect of Anlotinib on human oral cavity.The expression changes of the gene and protein levels of EMT markers in squamous cell line Cal27 cells after 24 hours.3.Analysis of experimental results: All experiments were repeated three times,and the experimental results were statistically analyzed,and P<0.05 was considered statistically significant.Results 1.Anlotinib has significant cytotoxicity against human oral squamous cell carcinoma cell line Cal27 cells(P<0.05),and the effect is dose-dependent.Arotinib significantly inhibited the migration of human oral squamous cell carcinoma cell line Cal27 cells(P<0.05).2.The gene and protein expression levels of EMT marker E-cad in the anlotinib-treated group were higher than those in the control group,and the difference was statistically significant(P<0.05).The expression of genes and proteins in the action group were lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusions 1.Anlotinib can significantly inhibit the proliferation and migration biological activities of human oral squamous cell carcinoma cells.2.Anlotinib can significantly inhibit the EMT process of human oral squamous cell carcinoma cells.3.Anlotinib can inhibit the EMT process of human oral squamous cell carcinoma cells by Down-regulation of EMT marker expression in human oral squamous cell carcinoma plays a therapeutic role in inhibiting the development and metastasis of oral squamous cell carcinoma.This not only suggests that arotinib has potential value in the efficient treatment of OSCC,but also may become a targeted therapeutic drug for OSCC.